Perrigo’s JB Labs Buy Could Cool Contract Manufacturing Competition
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's addition of needed manufacturing capacity via the $44 million acquisition of JB Laboratories dampens the contract manufacturing market that has developed to serve the private labeler during a period of rapid growth
You may also be interested in...
Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business
Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance
Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business
Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance
Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business
Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance